News | April 02, 2012

SAVI Studies Verify Favorable Cosmetic Outcomes with Precise Delivery of Radiation Therapy

Multi-Site Data Drawn from Over 1,000 Patients Details Advantages of Advanced Form of Breast Cancer Treatment

April 2, 2012 — Two new studies demonstrate the cosmetic and dosimetric advantages of the SAVI breast brachytherapy applicator for treatment of early-stage breast cancer.

The studies were presented as scientific posters at national medical conferences and were drawn from 12 centers participating in the SAVI Collaborative Research Group. Researchers reached two primary conclusions:

  1. SAVI radiation therapy provides for excellent or good cosmetic outcomes in the majority of patients.
  2. The device can safely and effectively treat the broadest range of women with accelerated partial breast irradiation (APBI), due to the precision with which the SAVI applicator can deliver the dose.

 

“These studies point to the fact that by minimizing radiation exposure to normal body structures, the SAVI device makes breast-conservation therapy available to many more women, especially for those with breast cancer close to the skin or chest wall,” said Constantine Mantz, M.D., a co-author on both studies and radiation oncologist and chief medical officer of 21st Century Oncology, the largest radiation oncology provider in the United States.

The SAVI Collaborative Research Group, from which the data was drawn, was established to study clinical outcomes of APBI treatment with the SAVI device. The data represents the largest subset of patients who have been treated with the SAVI applicator.

SAVI delivers a shortened course of radiation therapy for early-stage breast cancer patients following lumpectomy surgery. It is the only single-entry breast brachytherapy device that allows physicians to sculpt radiation based on patient-specific anatomy, which increases the number of women who can benefit from APBI. Clinical studies show that by providing targeted radiation where it is needed most, SAVI decreases toxicity and lowers the risk of cosmetic side effects.

In a scientific poster presented at the annual meeting of the National Interdisciplinary Breast Center Conference, researchers examined cosmetic outcomes with the device among a group of 1,010 patients. Median age of women in the study group was 63 years.

Researchers found highly favorable outcomes with regard to cosmetic results. They concluded that among patients with two-year follow-up, 91.6 percent had excellent or good cosmetic results – even when radiation was delivered near the surface of the skin, within 7 mm or less of the surface.

“We looked at cosmetic outcomes in part because it is important to our patients,” said Robert L. Hong, M.D., the presenter and medical director of radiation oncology at Virginia Hospital Center. “This data points toward an additional quality of life benefit from the therapy.”

The second poster was presented at the annual meeting of the American College of Radiation Oncology (ACRO). It examined elements of radiation dosimetry with the SAVI device. Data involving 817 patients drawn from 12 clinical sites demonstrated the device's dosimetric versatility and its ability to precisely deliver radiation.

“Compared to other APBI devices, the SAVI applicator is better able to sculpt and control the radiation dosage, to deliver therapy to the targeted area and to protect healthy structures such as the chest wall and skin,” said ?erban Morcovescu, M.S., the poster presenter and a board-certified medical physicist at Texas Oncology Denton, in Denton, Texas.

Even with minimal skin separation of 7 mm or less, the study data showed that the maximum dose to the skin rarely exceeded 100% of the prescription dose, thus eliminating skin spacing restrictions.

Breast-conservation therapy includes lumpectomy– the surgical removal of the cancerous tissue within the breast plus tissue immediately around the tumor – followed by radiation. This approach is an alternative to mastectomy, which removes the entire breast and is often followed by breast reconstruction.

Radiation treatment after a lumpectomy has traditionally involved irradiation of the entire breast with an external beam. Besides the inconvenience of the six-week-long regimen, many women must travel some distance to receive external-beam radiation. That can put additional stress on their families, jobs and financial resources.

For more information: www.ciannamedical.com.

Related Content

Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...